Cambridge Oncometrix
Haverhill
About Cambridge Oncometrix
Cambridge Oncometrix aims to save lives by enabling the early detection of prostate cancer - a condition that affects 1 in 7 men on the planet. The company develops a non-invasive risk stratification test for prostate cancer. The laboratory test will be capable of accurately selecting men for mpMRI-guided biopsy.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $3.0M
- Funding stage: Seed
- Last round: Grant (Feb 2020)
- Website: cambridgeoncometrix.com
- Phone: +441603 274 521
Industries & Categories
Biotechnology, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/cambridge-oncometrix-122548 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.